Nirogacestat and Cocktail of CYP Specific Probe Substrates not checked

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Drug: Nirogacestat 100 mg tablet Day 1 through Day 17 and Drug: Cocktail of CYP Specific Probe Substrates administered Day 15.”In the company’s words, NCT07259330 on ClinicalTrials.gov
Main trialPhase 1
“This study will evaluate the effects of nirogacestat 100 mg twice daily (BID) on the pharmacokinetics (PK) of a cytochrome P450 (CYP) cocktail.”In the company’s words, NCT07259330 on ClinicalTrials.gov

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 27 Mar 2026 To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Nirogacestat and Cocktail of CYP Specific Probe Substrates

Following is part of Solo: you see every change to Nirogacestat and Cocktail of CYP Specific Probe Substrates the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in